SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c; Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c; Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017

Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update

August 9, 2016 6:30 AM EDT

Portfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217

Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017

Dosing Commenced in Expanded Phase 2 Program for SAGE-547 in Moderate and Severe Postpartum Depression

Phase 2 Initiations Planned for SAGE-217 in Essential Tremor and Postpartum Depression in 2H 2016

Proof-of-Concept Study Initiations Planned with SAGE-547 in Major Depressive Disorder and SAGE-217 in Parkinsons Disease in 2H 2016

Conference Call Today at 8:00 AM ET

... More